Search

Your search keyword '"Poggio, F"' showing total 181 results

Search Constraints

Start Over You searched for: Author "Poggio, F" Remove constraint Author: "Poggio, F" Search Limiters Full Text Remove constraint Search Limiters: Full Text
181 results on '"Poggio, F"'

Search Results

1. Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial

2. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)

3. VISTA: A Promising Target for Cancer Immunotherapy?

4. 35P SNPs of aromatase gene (CYP19A1) and outcomes of patients with estrogen receptor-positive (ER+) early breast cancer (eBC) treated with aromatase inhibitors (AIs): A multicenter, prospective study

5. 108P Safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study)

6. 134O Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)

7. P-463 Anti-Müllerian hormone levels in breast cancer patients receiving chemotherapy with or without concurrent luteinizing hormone-releasing hormone agonist: results from the PROMISE phase III trial

8. 69P Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial

13. Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]

14. 307P Overall survival in metastatic breast cancer patients according to different follow up strategies for early breast cancer

15. 118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella

16. Production of pions, kaons and protons in pp collisions at $\sqrt{s}= 900~\mathrm{GeV}$ with ALICE at the LHC

17. Charged-particle multiplicity measurement in proton–proton collisions at $\sqrt{s}=7$ TeV with ALICE at LHC

18. Charged-particle multiplicity measurement in proton–proton collisions at $\sqrt{s}=0.9$ and 2.36 TeV with ALICE at LHC

19. First proton–proton collisions at the LHC as observed with the ALICE detector: measurement of the charged-particle pseudorapidity density at $\sqrt{s}=900$  GeV

20. 226P Impact of BMI on outcome and cardiac safety in HER2-positive breast cancer patients treated with adjuvant trastuzumab: Results of a monocentric observational study

21. 1740P Assessing the impact of COVID-19 outbreak on the attitudes and practice of Italian oncologists towards breast cancer care and related research activities

22. 1700P Perception and attitudes of Italian physicians towards the management of checkpoint inhibitors in oncology during COVID-19 outbreak: Results from a national survey

23. 95TiP Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC)

24. 148P Surgery (Sx) of the primary tumour in de novo metastatic breast cancer (BC) patients (pts) is associated with increased survival: A nationwide population-based study by the Belgian Cancer Registry (BCR) and the Belgian Society of Medical Oncology (BSMO)

25. Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: An exploratory analysis of the GIM2 trial

27. The role of dose-dense (DD) adjuvant chemotherapy (CT) in HER2-positive (HER2+) early breast cancer (BC) patients (pts) before and after the introduction of trastuzumab (T): Exploratory analysis of the GIM2 trial

28. Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab

30. Physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey

32. Abstract GS4-01: Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients

33. A Multigene Score based on gene-expression profiling as a prognostic tool in women with early stage, hormone receptor-positive/Her2-negative breast cancer

34. Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study

35. The Pregnancy and Fertility (PREFER) study: a prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts)

36. 186P - Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: An exploratory analysis of the GIM2 trial

37. The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients: an international multicentre hospital-based retrospective cohort study

41. Neoadjuvant therapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Her2 positive non operable breast cancer: a phase II study

42. An international multicentre hospital-based retrospective cohort study evaluating the prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients

43. TP53 germline mutation testing in early onset breast cancer

44. Concurrent versus sequential adjuvant chemo-endocrine therapy in early stage hormone receptor-positive breast cancer patients: a systematic review and meta-analysis

45. Dose-dence adjuvant chemotherapy in early breast cancer: the results of 15 years of follow-up

46. Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: a systematic review and meta-analysis of randomized studies

47. Does body mass index impact on clinical outcomes in her-2 positive metastatic breast cancer?

48. Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients

49. Correlation between treatment with aromatase inhibitors and carotid intima-media thickness, carotid stenosis and abdominal aortic diameter. A prospective cohort study

50. Prospective study of fertility preservation strategies in young early breast cancer patients: the PREFER (PREgnancy and FERtility) trial

Catalog

Books, media, physical & digital resources